drugset / Trial / NCT04799002

Topotecan and Melphalan for Retinoblastoma

NCT04799002

Phase 3 Recruiting 50 enrolled Sun Yat-sen University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Timeline

Start
2021-03-11
Primary completion
2024-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule Other
Comparator Topotecan Small molecule Other